Turner White CommunicationsAbout TWCSubscribeContact TWCHomeSearch
Hospital PhysicianJCOMSMPBRMsCart
Current Contents
Past Issue Archives
Interactive:
Self-Assessment Questions
Review of
Clinical Signs
Clinical Review
Quiz
Pediatric Rounds
Resident Grand Rounds
Article Archives
Case Reports
Clinical Practice
Exams
Pediatric Rounds
Resident Grand Rounds
Review of
Clinical Signs

Guide to Reading
Hospital Physician
Editorial Board
Information for Authors

Reprints, Permissions, & Copyright
Site Map
Self-Assessment Questions

Nephrology


Answer 5
  1. Furosemide and an ACE inhibitor. Treatment of idiopathic membranous nephropathy remains controversial due to a high spontaneous remission rate. Without treatment, generally one third of patients spontaneously remit, one third progress to renal failure, and one third remain unchanged.5 However, several general principles apply to the management of these patients, including diuretics to control edema, angiotensin inhibition to reduce proteinuria, and correction of hyperlipidemia.5 In selected patients with risk factors for progressive disease, such as presence of glomerular scarring, elevated serum creatinine at presentation, and proteinuria greater than 8 g/day, immunosuppressive therapy should be considered; however, glucocorticosteroids alone are not beneficial. Glucocorticosteroids should be combined with alkylating agents or calcineurin inhibitors to attain remission. Warfarin is indicated in patients at high risk for thromboembolism with massive proteinuria and an albumin level less than 2 g/dL and is not the initial step in management of membranous nephropathy.

    REFERENCE
    5.
     Perna A, Schieppati A, Zamora J, et al. Immunosuppressive treatment for idiopathic membranous nephropathy: a systematic review. Am J Kidney Dis 2004;44:385–401.

Click here to return to the questions

 

Hospital Physician     JCOM     Seminars in Medical Practice
Hospital Physician Board Review Manuals
About TWC    Subscribe    Contact TWC    Home    Search   Site Map

Copyright © 2009, Turner White Communications
Updated 9/22/08 • nvf